Related Experiment Videos
Human platelet alloantigens
1Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig University Giessen, Germany. sentot.santoso@immunologie.med.uni-giessen.de
Wiener Klinische Wochenschrift
|December 6, 2001
Summary
Alloantibodies targeting human platelet antigens cause various transfusion reactions and conditions like neonatal alloimmune thrombocytopenia. Current diagnostic methods are effective, with future innovations promising enhanced detection.
Area of Science:
- Immunology
- Transfusion Medicine
- Hematology
Background:
- Alloantibodies against human platelet membrane alloantigens cause significant clinical syndromes.
- Conditions include neonatal alloimmune thrombocytopenia (NAIT), post-transfusion purpura (PTP), and platelet transfusion refractoriness (PTR).
- Alloimmune reactions involving platelets are also observed after hematopoietic stem cell transplantation.
Purpose of the Study:
- To review the mechanisms and clinical significance of antibody formation against platelet alloantigens.
- To discuss the classification of platelet alloantigens (Type I and Type II) and their associated clinical conditions.
- To outline current diagnostic methods and future prospects for platelet antibody detection.
Main Methods:
- Review of existing literature on platelet alloantigens and alloimmunization.
- Discussion of molecular basis of platelet specific alloantigens, including mutations and glycoprotein conformation.
- Description of diagnostic assays such as MAIPA and immunobead assays.
Main Results:
- Type I alloantigens (ABO, HLA class I) are involved in PTR and febrile nonhemolytic transfusion reactions.
- Type II alloantigens are implicated in NAIT, PTP, and passive alloimmune thrombocytopenia.
- Platelet antigen expression varies, and many determinants rely on glycoprotein conformation rather than single mutations.
Conclusions:
- Understanding platelet alloantigens is crucial for managing transfusion reactions and related conditions.
- Current diagnostic assays are established, but advancements in phage display and recombinant antigens are expected to improve phenotyping and antibody detection.
- Further research into the complex nature of platelet alloantigens will enhance clinical management and patient outcomes.